Influenza activity is climbing sharply across the United States weeks ahead of its usual winter schedule, prompting infectious disease specialists to urge Americans to get vaccinated immediately. Surveillance data released by the Centers for Disease Control and Prevention indicates that positive influenza tests have multiplied rapidly since early September, driven almost entirely by a subtype that historically poses a greater threat to children and young adults.
An unseasonable spike driven by H1N1
CDC testing data published on Oct. 9 showed a national test positivity rate of 3.6 percent, representing a sixfold jump from the 0.6 percent registered at the identical time in 2025, Scientific American reported. More recent figures pushed positive test rates to 5 percent, marking an estimated 30 percent weekly climb, according to The Independent.
Regional outbreaks appear particularly acute in the American Southwest and Pacific. In federal Region 9—which includes California, Arizona, Nevada and Hawaii—positivity touched 9.5 percent, a metric researchers describe as exceptionally rare for early autumn. Among positive influenza A specimens analyzed nationally, 98.4 percent were identified as H1N1, while just 1.6 percent were the H3N2 subtype, Scientific American reported.
Andrew Pekosz, an immunologist at the Johns Hopkins Bloomberg School of Public Health, told Scientific American that such infection rates are typical for November or December rather than early fall. Pekosz noted that the circulating H1N1 strain shows signs of antigenic drift, meaning slight genetic shifts might permit it to bypass prior population immunity and spread with greater ease.
Vaccine match and lagging uptake
The subtype breakdown carries significant public health implications. While H3N2 seasons usually bring severe outcomes for older adults, H1N1 historically inflicts a disproportionate disease burden on younger demographics. However, both strains can produce critical illness in patients of any age.
Annual flu shots are formulated to defend against both types as well as influenza B. Scott Hensley, a microbiology professor at the University of Pennsylvania, told NBC News that the updated shot appears well matched to the circulating H3N2 variant, though its precise shield against the mutated H1N1 strain remains less clear.
Even so, medical leaders stress that imperfect protection still prevents life-threatening complications. CDC records estimate that annual influenza outbreaks generate between 9.4 million and 51 million illnesses and cause from 6,300 to 52,000 deaths across the country. Despite the threat, adult immunization fell to 41.9 percent during the 2024-2025 season, reaching its lowest point in seven seasons, The Independent reported.
“It’s not just a cold,” Dr. Ryan Stanton, president-elect of the American College of Emergency Physicians, said during a news briefing, as reported by AARP. “A lot of these [respiratory viruses] are much, much more serious.”
Timing shots and expanding options
Physicians emphasize that getting inoculated early offers crucial defense before community transmission peaks. Dr. Trish Perl, an infectious disease specialist at UT Southwestern Medical Center, told Scientific American that individuals should receive their shots before Thanksgiving gatherings trigger further spread. Protection typically develops roughly two weeks after injection and remains strongest for three to six months.
For older Americans, a new immunization option cleared regulatory review earlier this year. The Food and Drug Administration approved Moderna’s mFLUSIVA on Aug. 5, making it the first seasonal mRNA flu shot authorized for adults 50 and older. In late-stage trials, the mRNA shot proved 26.6 percent more effective at preventing flu than standard vaccines, Scientific American reported. Nevertheless, access to the product remains limited, complicated by regulatory scheduling under the CDC Advisory Committee on Immunization Practices.
With winter approaching, health experts advise anyone showing symptoms to consult clinicians quickly about prescription antiviral medications, such as Tamiflu, which can shorten the course of illness and curtail contagiousness.
